Neuroone Medical Technologies (NMTC) Gains from Sales and Divestitures (2022 - 2026)

Neuroone Medical Technologies has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $51983.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 4.43% year-over-year to $51983.0; the trailing twelve-month figure through Mar 2026 stood at $51983.0 (down 4.43% YoY), and the FY2025 full-year result was $397900.0, up 47.19% from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $51983.0, up from $36417.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $397900.0 in Q3 2025, with the low at $32535.0 in Q1 2024.
• Historically, Gains from Sales and Divestitures has averaged $149108.4 across 5 years, with a median of $52299.0 in 2023.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures surged 716.73% — and 2024, when it declined 18.52%.
• Neuroone Medical Technologies' Gains from Sales and Divestitures stood at $40624.0 in 2022, then slipped by 7.25% to $37679.0 in 2023, then climbed by 0.35% to $37809.0 in 2024, then decreased by 3.68% to $36417.0 in 2025, then soared by 42.74% to $51983.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $51983.0 (Q1 2026), $36417.0 (Q4 2025), and $397900.0 (Q3 2025), per Business Quant data.